Stockreport

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placeme...

Rapport Therapeutics, Inc.  (RAPP) 
PDF BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and deve [Read more]